News25/Ratings12
Price$8.70-0.58 (-6.25%)
02:00 PM07:15 PM
News · 26 weeks52-50%
2026-04-192026-10-11
Mix2090d
- Other8(40%)
- Insider8(40%)
- SEC Filings4(20%)
Latest news
25 items- PRKorro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to two newly hired employees. Korro granted the new employees nonstatutory stock options to purchase 4,000 shares of Korro’s common stock, in the aggregate, at an exercise price of $8.88 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, October 14, 2026. The options each have a te
- SECSEC Form 8-K filed by Korro Bio Inc.8-K - Korro Bio, Inc. (0001703647) (Filer)
- PRKorro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background Administered a single dose of 2mg/kg to the first cohort of healthy volunteersExpected to start dosing in UCD patients in the first half of 2027 with an interim readout expected in the second half of 2027 CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, announced today that the first cohort of participants has been dose
- INSIDERDirector Formela Jean Francois sold $686,177 worth of shares (48,690 units at $14.09) as part of a pre-agreed trading plan (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERSenior Vice President, Finance Dolan Oliver sold $69 worth of shares (5 units at $13.72) as part of a pre-agreed trading plan, decreasing direct ownership by 0.03% to 16,241 units (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- PRKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to three newly hired employees. Korro granted the new employees nonstatutory stock options to purchase 5,000 shares of Korro’s common stock, in the aggregate, at an exercise price of $12.93 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, September 9, 2026. The options each have a ten-year ter
- INSIDERSenior Vice President, Finance Dolan Oliver sold $99,368 worth of shares (7,353 units at $13.51) as part of a pre-agreed trading plan, decreasing direct ownership by 31% to 16,246 units (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERDirector Formela Jean Francois sold $4,188 worth of shares (300 units at $13.96) as part of a pre-agreed trading plan (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- PRKorro to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences: Citi 2026 Biopharma Back to School SummitFormat: Fireside chat moderated by Yigal Nochomovitz, Ph.D., Director, Biotech Equity Research, CitiDate: September 9th, 2026Time: 8:40 AM ET 2026 Cantor Global Healthcare ConferenceFormat: Fireside chat moderated by Steve Seedhouse, Biotechnology Eq
- INSIDERDirector Formela Jean Francois sold $398,552 worth of shares (28,468 units at $14.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- SECKorro Bio Inc. filed SEC Form 8-K: Other Events8-K - Korro Bio, Inc. (0001703647) (Filer)
- PRKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 600 shares of Korro’s common stock at an exercise price of $13.35 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, August 12, 2026. The option has a ten-year term and vests over four years, with
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Korro Bio Inc.SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)
- INSIDERDirector Formela Jean Francois sold $29,916 worth of shares (2,143 units at $13.96) as part of a pre-agreed trading plan (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERLarge owner Lynx1 Capital Management Lp bought $78,809 worth of shares (6,684 units at $11.79) (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- SECSEC Form 10-Q filed by Korro Bio Inc.10-Q - Korro Bio, Inc. (0001703647) (Filer)
- SECKorro Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Korro Bio, Inc. (0001703647) (Filer)
- PRKorro Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateKRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation from the European Medicines Agency (EMA) for KRRO-121 for patients with urea cycle disorders (UCDs) Nominated KRRO-111 as development candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD); potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Ended second quarter 2026 with $137.9 million in cash, cash equivalents and marketable securities; provides sufficient resour
- INSIDERPresident and CEO Aiyar Ram sold $62,917 worth of shares (5,802 units at $10.84), decreasing direct ownership by 8% to 69,046 units (SEC Form 4) (tax liability)4 - Korro Bio, Inc. (0001703647) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Korro Bio Inc.SCHEDULE 13G - Korro Bio, Inc. (0001703647) (Subject)
- INSIDERChief Scientific Officer Vincent Loic A was granted 7,500 shares, increasing direct ownership by 41% to 25,797 units (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERSenior Vice President, Finance Dolan Oliver was granted 5,500 shares, increasing direct ownership by 30% to 23,599 units (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERGeneral Counsel Cerio Jeffrey was granted 6,500 shares, increasing direct ownership by 18% to 41,793 units (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERChief Operating Officer Chappell Todd was granted 7,500 shares, increasing direct ownership by 44% to 24,464 units (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- PRKorro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to seven newly hired employees. Korro granted four new employees nonstatutory stock options to purchase 6,000 shares, in the aggregate, of Korro’s common stock at an exercise price of $10.59 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, June 10, 2026; and granted three new employees nonstatut
KRRO FAQ
6 questionsWhere does KRRO stock trade?
Korro Bio Inc. (KRRO) is listed on NASDAQ.What sector and industry is KRRO in?
Korro Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Korro Bio Inc. go public?
Korro Bio Inc. (KRRO) completed its IPO in 2019.What are analysts saying about KRRO?
Korro Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $2100.00 price target on 2026-05-18. Recent price targets range from $1500.00 to $3000.00.What companies are similar to KRRO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KRRO side-by-side with any of them on Quantisnow.How can I track KRRO on Quantisnow?
Quantisnow aggregates Korro Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KRRO to receive live email and push alerts on every new disclosure.